



J. B. Chemicals & Pharmaceuticals Limited

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2011

(Rs.in Lakhs)

SR. NO.	PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31/12/2011 (Unaudited)	30/09/2011 (Unaudited)	31/12/2010 (Unaudited)	31/12/2011 (Unaudited)	31/12/2010 (Unaudited)	31/03/2011 (Audited)
1	a) Net Sales (Net of excise)	14,955.91	16,077.14	21,667.77	48,777.46	60,868.88	78,757.94
	b) Other Operating Income	587.95	3,287.93	548.04	4,387.98	1,415.52	1,912.61
	Total Income	15,543.86	19,365.07	22,215.81	53,165.44	62,284.40	80,670.55
2	Expenditure						
	a) (Increase)/Decrease in Stock in Trade & WIP	420.22	500.01	(898.94)	1,162.50	(321.24)	(1,286.13)
	b) Consumption of Raw Materials	4,877.16	5,718.18	5,999.03	15,705.25	15,780.39	20,900.33
	c) Purchase of Traded Goods	1,391.45	1,322.75	865.26	4,102.87	3,540.05	4,691.52
	d) Employees Cost	2,257.89	2,130.96	3,422.20	7,499.15	8,823.34	11,642.70
	e) Depreciation	562.94	567.50	602.30	1,697.94	1,697.30	2,265.08
	f) Sales Promotion & Publicity	587.37	1,015.00	3,356.41	2,856.41	7,554.04	10,527.89
	g) Exchange Fluctuation Suffered (Gain)/Loss	1,039.10	(134.49)	(37.91)	899.29	216.85	16.75
	h) Other Expenditure	4,041.86	4,301.91	4,602.47	12,212.55	12,707.25	17,234.34
	Total	15,177.99	15,421.82	17,910.82	46,135.96	49,997.98	65,992.48
3	Profit from operations before Other Income & Interest (1-2)	365.87	3,943.25	4,304.99	7,029.48	12,286.42	14,678.07
4	Other Income	624.15	1,361.63	140.85	2,404.11	378.01	586.79
5	Profit before Interest (3+4)	990.02	5,304.88	4,445.84	9,433.59	12,664.43	15,264.86
6	Interest	493.69	186.34	158.84	860.69	547.01	737.30
7	Profit after Interest but before Exchange Fluctuation Gain / (Loss) (5-6)	496.33	5,118.54	4,287.00	8,572.90	12,117.42	14,527.56
8	Exchange Fluctuation Gain / (Loss)	(2,326.90)	(1,912.93)	304.43	(4,509.63)	194.80	(422.22)
9	Profit/(Loss) after Interest but before Exceptional Items (7-8)	(1,830.57)	3,205.61	4,591.43	4,063.27	12,312.22	14,105.34
10	Exceptional Income (Net)	0.00	76,059.34	-	76,059.34	-	-
11	Profit/(Loss) from Ordinary Activities Before Tax (9+10)	(1,830.57)	79,264.95	4,591.43	80,122.61	12,312.22	14,105.34
12	Tax Expenses :						
	Current Tax	(1,371.00)	17,203.00	918.00	16,585.00	2,462.00	2,810.00
	MAT Credit Entitlement	-	-	(70.00)	-	(410.00)	(550.00)
	Deferred Tax	57.31	66.61	(68.89)	154.23	(80.35)	19.63
	Short/(Excess) Provision for Taxation for prior year	-	-	-	-	(2.34)	6.25
13	Profit/(Loss) from Ordinary Activities After Tax (11-12)	(516.88)	61,995.34	3,812.32	63,383.38	10,342.91	11,819.46
14	Paid-up Equity Share Capital (Face Value Rs. 2/- per share)	1,694.15	1,694.10	1,689.92	1,694.15	1,689.92	1,690.34
15	Reserves (excluding Revaluation Reserve) as per balance sheet of previous accounting year	-	-	-	-	-	69,637.93
16	Earnings Per Share (EPS)						
	a) Basic (Not annualised)	(0.61)	73.30	4.52	74.90	12.25	14.00
	b) Diluted (Not annualised)	(0.61)	73.15	4.51	74.86	12.23	13.96
17	Public Shareholding						
	No. of shares	37,853,210	37,850,710	37,642,460	37,853,210	37,642,460	37,663,735
	% of shareholding	44.69	44.69	44.55	44.69	44.55	44.56
18	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of shares	-	-	-	-	-	-
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	Number of shares	46,854,090	46,854,090	46,853,590	46,854,090	46,853,590	46,853,090
	Percentage of shares (as a % of the shareholding of promoter and promoter group)	100	100	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	55.31	55.31	55.45	55.31	55.45	55.44

NOTES :

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on January 25, 2012.
2. The statutory auditors have carried out a limited review of the above unaudited financial results for the quarter and nine months ended on December 31, 2011.
3. The quarter continued to witness volatility in Rupee - US\$ rate movement. Consequently, the results for the quarter were significantly affected by exchange fluctuation loss (translation) provision of Rs.2326.90 Lacs made consequent to further weakening of Rupee during the quarter.
4. The figures for the previous quarter/nine months ended December, 2010, include figures of Russia-CIS OTC business, which has been divested during the year. Therefore, the figures are strictly not comparable.
5. There were no outstanding investor complaints at the beginning of the quarter. The company received 11 complaints from the investors during the quarter, which have been disposed of during the quarter.
6. The company is engaged in a single segment of activity namely, "Pharmaceuticals".
7. During the quarter, the company allotted 2,500 equity shares against exercise of stock options.
8. Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary.

For J.B. CHEMICALS & PHARMACEUTICALS LTD.

Place : Mumbai
Date : January 25, 2012

J.B.MODY
CHAIRMAN & MANAGING DIRECTOR